DMD Large equally mixed donor pool

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Drug Metabolism and Disposition Fast Forward
First published on December 31, 2008; DOI: 10.1124/dmd.108.023895


0090-9556/09/3704-794-801$20.00
DMD 37:794-801, 2009

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dmd.108.023895v1
37/4/794    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Herédi-Szabó, K.
Right arrow Articles by Krajcsi, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Herédi-Szabó, K.
Right arrow Articles by Krajcsi, P.

Multidrug Resistance Protein 2-Mediated Estradiol-17β-D-glucuronide Transport Potentiation: In Vitro-in Vivo Correlation and Species Specificity

K. Herédi-Szabó1, H. Glavinas1, E. Kis, D. Méhn, G. Báthori, Z. Veres, L. Kóbori, O. von Richter, K. Jemnitz, and P. Krajcsi

Solvo Biotechnology, Szeged, Hungary (K.H.-S., H.G., E.K., D.M., G.B., P.K.); Chemical Research Institute, HAS, Budapest, Hungary (Z.V., L.K., K.J.); and Aicuris, Wuppertal, Germany (O.v.R.)

Multidrug resistance protein 2 (MRP2) is a multispecific organic anion transporter expressed at important pharmacological barriers, including the canalicular membrane of hepatocytes. At this location it is involved in the elimination of both endogenous and exogenous waste products, mostly as conjugates, to the bile. Estradiol-17β-D-glucuronide (E217βG), a widely studied endogenous substrate of MRP2, was shown earlier to recognize two binding sites of the transporter in vesicular transport assays. MRP2 modulators (substrates and nonsubstrates) potentiate the transport of E217βG by MRP2. We correlated data obtained from studies of different complexities and investigated the species-specific differences between rat and human MRP2-mediated transport. We used vesicular transport assays, sandwich-cultured primary hepatocytes, and in vivo biliary efflux in rats. Our results demonstrate that the rat Mrp2 transporter, unlike the human MRP2, transports E217βG according to Michaelis-Menten type kinetics. Nevertheless, in the presence of modulator drugs E217βG transport mediated by the rat transporter also shows cooperative kinetics as potentiation of E217βG transport was observed in the vesicular transport assay. We also demonstrated that the potentiation exists both in rat and in human hepatocytes and in vivo in rats.


Address correspondence to: Dr. Peter Krajcsi, Solvo Biotechnology, Gyár u 2, Budaörs, Hungary 2040. E-mail: krajcsi{at}solvo.hu







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2009 by the American Society for Pharmacology and Experimental Therapeutics.